Video
Dr. Powell Discusses the Next Steps for CPI-613
Author(s):
In Partnership With:
Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.
Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.
Following a phase I trial, researchers plan to move forward with CPI-613, focusing on myelodysplastic syndrome. In the study, 3/3 patients with very refractory disease responded to treatment, which is encouraging, Powell says, though represents just a hint of activity.
CPI-613 will also be analyzed in acute myeloid leukemia, where activity was seen, in combination with high-dose cytarabine. Cytarabine is an effective treatment for patients with relapsed/refractory disease and the combination will be evaluated for tolerance and efficacy.
